1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
LidarCLIP or : How i Learned to Talk to Point Clouds
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
- 2023
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
(
- Contribution to journal › Article
- 2018
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
- 2017
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(
- Contribution to journal › Article
- 2016
-
Mark
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
(
- Contribution to journal › Article
- 2013
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
(
- Contribution to journal › Article
- 2010
-
Mark
90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma First Results from an International Phase II Clinical Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good Prognosis Diffuse Large B Cell Lymphoma (DLBCL) Results of the 6 Year Follow up of the Mint Study of the Mabthera International Trial (Mint) Group
(
- Contribution to journal › Published meeting abstract